124 related articles for article (PubMed ID: 7540468)
21. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
[TBL] [Abstract][Full Text] [Related]
22. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
23. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
24. [Current possibilities in immunotherapy of cancer].
von Fliedner V
Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061
[TBL] [Abstract][Full Text] [Related]
25. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
26. Current role of immunotherapy in multiple myeloma.
Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
[TBL] [Abstract][Full Text] [Related]
27. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
28. [Advances in the pathogenesis, biology, and management of multiple myeloma].
Kosaka M
Rinsho Byori; 1996 Aug; 44(8):743-9. PubMed ID: 8816060
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
van de Donk NW; Kamps S; Mutis T; Lokhorst HM
Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
[TBL] [Abstract][Full Text] [Related]
30. Production and characterization of monoclonal antibodies (MoAbs) for the ex vivo purging of the bone marrow in patients with multiple myeloma.
Dinota A; Tazzari PL; Bontadini A; Grassi GP; Cerato C; Motta MR; Visani G; Cavo M; Gobbi M; Tura S
J Exp Pathol; 1987; 3(4):363-7. PubMed ID: 3331648
[No Abstract] [Full Text] [Related]
31. Immunotherapy with autologous bone-marrow transplantation: rationale and results.
Bilgrami S; Silva M; Cardoso A; Miller KB; Ascensao JL
Exp Hematol; 1994 Oct; 22(11):1039-50. PubMed ID: 7523161
[No Abstract] [Full Text] [Related]
32. Humoral immunotherapy of multiple myeloma: perspectives and perplexities.
Di Bernardo A; Macor P; Guarnotta C; Franco G; Florena AM; Tedesco F; Tripodo C
Expert Opin Biol Ther; 2010 Jun; 10(6):863-73. PubMed ID: 20367529
[TBL] [Abstract][Full Text] [Related]
33. Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.
Chen YH; Shiao RT; Labayog JM; Modi S; Lavelle D
Leuk Lymphoma; 1997 Sep; 27(1-2):11-23. PubMed ID: 9373192
[TBL] [Abstract][Full Text] [Related]
34. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
[TBL] [Abstract][Full Text] [Related]
35. Receptor-targeted immunotherapy.
Janson RW; Arend WP
Bull Rheum Dis; 1992; 41(3):6-8. PubMed ID: 1617334
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody-based immunotherapy for multiple myeloma.
Danylesko I; Beider K; Shimoni A; Nagler A
Immunotherapy; 2012 Sep; 4(9):919-38. PubMed ID: 23046236
[TBL] [Abstract][Full Text] [Related]
37. [New therapeutic approaches in multiple myeloma].
Harousseau JL
Ann Med Interne (Paris); 1989; 140(1):45-9. PubMed ID: 2472083
[No Abstract] [Full Text] [Related]
38. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
Fulciniti M; Hideshima T; Vermot-Desroches C; Pozzi S; Nanjappa P; Shen Z; Patel N; Smith ES; Wang W; Prabhala R; Tai YT; Tassone P; Anderson KC; Munshi NC
Clin Cancer Res; 2009 Dec; 15(23):7144-52. PubMed ID: 19934301
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal gammopathy as a model for B-cell differentiation: from "paraprotein" to artificial antibodies.
Bast EJ; van Camp B
Neth J Med; 1991 Oct; 39(3-4):209-15. PubMed ID: 1791883
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
